Related Experiment Video
Updated: Dec 14, 2025

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
Pharmacotherapics Advice in Guidelines for COVID-19
Zhang-Ren Chen1, Ying Zhou1, Jin Liu1
1Department of Pharmacy, The First Affiliated Hospital of Nanchang University, Nanchang, China.
This review summarizes COVID-19 pharmacotherapy guidelines and updates. It examines the efficacy and safety of anti-coronavirus disease 2019 drugs like chloroquine and tocilizumab.
Area of Science:
- Pharmacology
- Infectious Diseases
- Public Health
Background:
- Coronavirus disease 2019 (COVID-19) rapidly emerged in late 2019, causing a global pandemic.
- Limited effective treatments necessitated rapid development and guideline dissemination for COVID-19 pharmacotherapy.
- International clinical trials informed treatment recommendations, leading to published guidelines from various countries and organizations.
Purpose of the Study:
- To consolidate and analyze pharmacotherapy recommendations for COVID-19 from global guidelines.
- To highlight recent updates and changes in COVID-19 treatment guidelines.
- To critically review the efficacy and safety profiles of key anti-COVID-19 medications.
Main Methods:
- Systematic review of national and international clinical guidelines for COVID-19 treatment.
- Analysis of published data on the efficacy and safety of drugs recommended in guidelines.
- Comparative assessment of pharmacotherapeutic strategies based on guideline updates.
Main Results:
- Multiple pharmacotherapeutic options were proposed, including chloroquine and tocilizumab, with varying levels of evidence.
- Guidelines evolved significantly between December 2019 and May 2020, reflecting emerging clinical data.
- Efficacy and safety data for many anti-COVID-19 drugs remain under investigation, necessitating cautious application.
Conclusions:
- Pharmacotherapy for COVID-19 is guided by evolving international recommendations.
- Continuous evaluation of drug efficacy and safety is crucial for optimizing patient outcomes.
- Further research is essential to establish definitive treatments for coronavirus disease 2019.
More Related Videos
11:17Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
09:03Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic
Published on: November 7, 2020
Related Concept Videos
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Myocarditis III: Medical Management
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Drug Therapy
Antianxiety Medications
Pharmacokinetics in Pediatric Patients: Drug Excretion